Table 1.

Baseline characteristics among patients with AI and among those without AI.

	Patients with AI (n  = 20)	Patients without AI (n  = 121)	P -value
Age in years (mean ± s.d.)	55 ± 12.02	58.31 ± 15.57	0.37
Male gender (%)	55	50.4	0.42
Weight in kg (mean ± s.d.)	64.2 ± 8.45	64.95 ± 13.35	0.81
eGFR in mL/min/1.73 m² (mean ± s.d.)	116.76 ± 74.88	102.46 ± 44.79	0.24
Serum sodium in mmol/L (mean ± s.d.)	126.05 ± 5.86	125.13 ± 7.67	0.61
Biochemical severity
1. Mild (%)  2. Moderate (%)  3. Profound (%)	6 (30.0) 7 (35.0) 7 (35.0)	38 (31.4) 47 (38.8) 36 (29.8)	0.89
TSH levels in mIU/L (mean ± s.d.)	8.69 ± 21.09	3.31 ± 4.55	0.01
Free T4 in pmol/L (mean ± s.d.)	17.54 ± 9.65	17.42 ± 5.71	0.94
Basal cortisol values in μg/dL (mean ± s.d.)	5.58 ± 3.80	15.78 ± 8.70	0.00
Post-APST – 60 min cortisol in μg/dL (mean ± s.d.)	13.04 ± 3.20	28.32 ± 10.74	0.00

Mild hyponatremia (serum sodium between 130 and134 mmol/L), moderate (serum sodium between 125 and 129 mmol/L) and profound (serum sodium <125 mmol/L).

APST, Acton Prolongatum™ stimulation test; AI, adrenal insufficiency; eGFR, estimated glomerular filtration rate by modification in diet in renal disease formula; TSH, thyroid-stimulating hormone.